The agents currently in use can target either Programmed Death-1 Receptor (PD-1) and Cytotoxic T Lymphocyte Associated Protein-4 (CTLA-4) located on T cells, or Programmed Death Ligand-1 (PD-L1) located on tumor cells, thus counteracting the main mechanisms by which tumor cells exploit the immune response and generate immune tolerance towards tumor cells. This evidence concerns the gene CD274 and neoplasm.